A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

NCT05199285 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Sponsor has withdrawn support for the study.

Conditions

BCLC Stage B Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma
Locally Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IVA Hepatocellular Carcinoma AJCC v8
Stage IVB Hepatocellular Carcinoma AJCC v8
Unresectable Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]